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Background. Hypercholesterolemia and disruptions of the blood brain barrier (BBB) have been implicated as underlying
mechanisms in the pathogenesis of Alzheimer’s disease (AD). Simvastatin therapy may be of beneﬁt in treating AD; however, its
mechanismhasnotbeenyetfullyunderstood.Objective.ToexplorewhethersimvastatincouldblockdisruptionofBBBinducedby
cholesterol both in vivo and in vitro. Methods. New Zealand rabbits were fed cholesterol-enriched diet with or without simvastatin.
Total cholesterol of serum and brain was measured. BBB dysfunction was evaluated. To further test the results in vivo, rat brain
microvascular endothelial cells (RBMECs) were stimulated with cholesterol in the presence/absence of simvastatin in vitro. BBB
disruptionwas evaluated. Results.Simvastatin blocked cholesterol-richdiet induced leakage of Evan’s blue dye. Cholesterolcontent
intheserumwasaﬀectedbysimvastatin,butnotbraincholesterol.Simvastatinblockedhigh-cholesterolmedium-induceddecrease
in TEER and increase in transendothelial FITC-labeled BSA Passage in RBMECs. Conclusions. The present study ﬁrstly shows that
simvastatin improves disturbed BBB function both in vivo and in vitro. Our data provide that simvastatin may be useful for
attenuating disturbed BBB mediated by hypercholesterolemia.
1.Introduction
The blood-brain barrier (BBB), a barrier between the central
nervous system (CNS) and the systemic circulation, main-
tains homeostasis within the brain microenvironment. The
anatomicalsubstrateoftheBBBisthecerebralmicrovascular
endothelium,which,togetherwithastrocytes,pericytes,neu-
rons,andtheextracellularmatrix,constitutesa“neurovascu-
lar unit” that is essential for the health and function of the
CNS. Failure of the BBB is a critical event in the progression
of several diseases, such as Alzheimer’s disease (AD) [1–4].
BBB breakdown is accompanied by an increase in the trans-
endothelial permeability to substances, which can damage
the microenvironment of the brain and aﬀect the structure
and function of the CNS. Therefore, it is not surprising
that strategies have been developed to “repair” the BBB in
order to restore normal brain homeostasis and prevent the
inﬁltration of pharmacologically active (noxious) substances
into the brain. Cholesterol is one of the most notorious
natural risk factors for arteriosclerotic cerebrovascular dis-
ease [5, 6]. Mounting evidence suggests that cholesterol
also plays a critical role in the early stage of AD [7–9].
Hypercholesterolemia leads to increased BBB leakage, an
eﬀectthatmaycontributetoADpathogenesis[10,11].Thus,
blocking BBB disruption may have beneﬁcial eﬀects against
AD caused by hypercholesterolemia. Several epidemiological
studies have revealed that cholesterol-lowering statins, which
are used for the treatment of coronary arterial disease, are
associated with a decreased risk of developing AD. However,
themechanismsunderlyingthiseﬀectremainunclear[8,12].
Statins have been shown to ameliorate BBB dysfunction
resulting from a number of conditions, including diabetes,
transient focal cerebral ischemia, and HIV-1 [13–15]. How-
ever, the eﬀects of statins on BBB disruptions induced by
hypercholesterolemia have not been reported. To address
this question, the permeability of the BBB was studied in
vivo using rabbits fed a cholesterol-enriched diet and treated
with simvastatin, a widely used natural statin derived from2 International Journal of Alzheimer’s Disease
fermentation. The eﬀect of simvastatin on BBB was also
performed using rat brain microvascular endothelial cells
(RBMECs) cultured under high-cholesterol conditions in
vitro.
2.MaterialsandMethods
2.1. Chemicals. Simvastatin capsules used in vivo were pur-
chased from Nantong Hua Pharmaceutical Co., Ltd (Jiangsu,
China). The simvastatin used in vitro and Evans blue dye
were obtained from Sigma (St. Louis, MO, USA). Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM), fetal bovine serum
(FBS), streptomycin, penicillin, DNase I, collagenase, col-
lagenase/dispase, and ﬂuorescein-isothiocyanate-conjugated
bovine serum albumin (FITC-BSA) were obtained from
Invitrogen (Carlsbad, CA, USA). Antibodies to ZO-1 and
occludin were purchased from Zymed (San Francisco, CA,
USA).
2.2. Animals and Treatment. Twenty-four adult male New
ZealandWhiterabbits(2356 ±212g)wereusedinthisstudy.
Rabbits were housed individually in the rabbit facility and
were kept on a 12h light/12h dark cycle at 28 ± 2◦Ca n d
37–48% humidity. Animals were randomly assigned to three
groups. The control diet group (n = 8) consisted of rabbits
that received normal rabbit chow for 10 weeks. The other
rabbits were fed chow supplemented with 2% cholesterol
for 6 weeks and were then randomly assigned to either the
cholesterol group (n = 8), which was fed chow supplemented
with 2% cholesterol or the cholesterol + simvastatin group
(n = 8), which was fed chow supplemented with 2%
cholesterol and 5mg/kg/d simvastatin for an additional 4
weeks. The olfactory bulbs, brain regions with an intact BBB
undernormalphysiologicalconditions,havebeenimplicated
in Alzheimer’s disease by studies reporting that AD patients
experience olfactory dysfunction [16]. Other research has
shown that the hippocampus is characterized by a selective
fragility of the BBB and is often aﬀected by AD pathology
early in the disease process [17]. Accordingly, the olfactory
bulbs and hippocampus were two primary brain areas
examinedinthisstudy.Allexperimentswereapprovedbythe
Committee for Animal Care and Use at Tianjin University of
Traditional Chinese Medicine.
2.3. Evan’s Blue Leakage Assay. To assay BBB permeability,
Evans blue dye (4%; 25mg/kg) was injected into rabbits
through the ear vein and allowed to circulate for 3h before
the animals were anesthetized with pentobarbital sodium
salt (30mg/kg). While deeply anesthetized, animals were
perfused with 37◦C saline via the left cardiac ventricle to
wash out any vascular Evans blue. Following perfusion,
brains were quickly removed, and the olfactory bulbs and
hippocampi were isolated, weighed, and incubated for 72h
with formamide in the dark at room temperature (25◦C).
After incubation, samples were centrifuged at 10,000×gf o r
10min, supernatants were collected, and the absorbance was
determined (Ex 620nm and Em 680nm) witha JascoFP-777
spectroﬂuorimeter (Jasco UK Ltd, Essex, UK). Evan’s blue
concentrations were calculated from standard curves, and
results were expressed as Evan’s blue/specimen wet weight
[18].
2.4. Immunohistochemistry. To evaluate the expression of
the tight junction proteins, occludin and zonula occluden-1
(ZO-1),cryostatbrainsections(10μm)oftheolfactorybulbs
and hippocampi were ﬁxed with acetone and then rinsed 3
times in 0.01M PBS for 5min each. Fluorescently labeled
primary antibodies against ZO-1 (Zymed, clone ZO1-1A12,
dilution 1:200) and occludin (Zymed, clone OC-3F10,
dilution 1:200) were diluted in PBS containing 1% Triton
X-100, applied to the brain sections and incubated overnight
at 4◦C in a dark humidiﬁed chamber. Sections were rinsed 3
times in 0.01M PBS for 5min each and were subsequently
examined by Leica microscopy. Images were analyzed with
Image J software.
2.5. Serum and Brain Cholesterol Measurements. Total serum
cholesterol was measured in venous blood collected from
rabbit ear veins using standard enzymatic techniques with
a Fully Automatic Biochemistry Analyzer. Following per-
fusion, brains were removed quickly and the cortex and
hippocampus were removed and weighed. Cholesterol levels
inthecortexandhippocampusweremeasuredusingreverse-
phase HPLC (ZORBAX XDB C18 4.6 × 250mm Spheri-
5RPC18column,5μm, Agilent, ﬂow rate, 0.8mL/min) with
Varian Prostar 325 ultraviolet detection at 208nm and LC
Workstation V6.2 Chromatographic Data System.
2.6. Primary Culture and Treatment of Rat Brain Microvessel
Endothelial Cells. Primary cultures of rat brain microvessel
endothelial cells (RBMECs) were isolated from Wistar rat
(approximately 100g) brains using a combination of enzyme
digestion and ultracentrifugation approaches as described
previously [19], with minor modiﬁcations. In brief, fresh rat
brainswereobtained,andthesurfacevesselsandmeningesof
thebrainswereremoved.Thegreymatterwascutinto1mm3
pieces, digested with 39U/mL DNase I and 0.7mg/mL
collagenase at 37◦C for 1h, and centrifuged at 1000×gf o r
10min. After centrifugation, the supernatant was discarded,
20% BSA was added, and the resulting mixture was cen-
trifuged at 1000×g for 20min. The dark red pellet was
collected and subjected to further enzymatic digestion in
39U/mL DNase I and 1mg/mL collagenase/dispase for 1h.
After centrifugation, the supernatant was discarded, and
brain capillary fragments were seeded onto matrigel-coated
Transwell ﬁlters (a pore size of 0.4μm Transwell, Corning
Life Sciences, USA) in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 20% FBS, 100μg/mL heparin, 30μg/mL
ECGF, and 2mM glutamine. The purity of RBMECs was
>95% as determined by factor-VIII-related antigen and
immunocytochemical staining (data not shown). These
cultures, which were used as an in vitro model of the
BBB, were maintained for 8–10 days to obtain conﬂuence
priortostartingexperiments.WhenastabletransendothelialInternational Journal of Alzheimer’s Disease 3
electrical resistance (TEER) value was obtained, the cultures
were washed twice with serum-free DMEM and treated with
water-soluble cholesterol (10μM) for 24h with or without
simvastatin (5μM) to evaluate disruption transendothelial
permeability [20].
2.7. Transendothelial Electrical Resistance (TEER) Measure-
ment with RBMECs. TEER was measured using a Millicell-
ERS electrical resistance apparatus (Millipore, Eschborn,
Germany) 24h after treatment with simvastatin. To study
the eﬀects of simvastatin on TEER, the Transwell inserts
withtheRBMECsculturesmentionedabovewereplacedinto
the chamber electrode ﬁlled with HEPES-buﬀered (25mM)
serum-free DMEM [21]. The symmetrically apposing elec-
trodes were situated above and beneath the membrane,
allowing a uniform current density to ﬂow across the mem-
brane. The resistance was recorded when the meter indicated
a stable resistance. Resistance values of multiple transwell
inserts from each experimental group were expressed in
common units (Ω/cm2) after subtracting the value of a blank
cell-free ﬁlter.
2.8. Measurement of Transendothelial Protein Passage. Tran-
sendothelial permeability to macromolecules was assessed
by passage of ﬂuorescein isothiocyanate-conjugated bovine
serum albumin (FITC-BSA) across the monolayer as
described previously [22]. In brief, primary RBMECs were
treated with cholesterol in the presence/absence of simvas-
tatin as mentioned above. FITC-BSA (50μg/mL) was added
to the upper chambers and its diﬀusion across the model
BBB was monitored using an FL600 microplate ﬂuorescent
reader (Biotek, Winooski, VT) (Ex 488nm, Em 525nm)
3h after the addition of FITC-BSA. BBB permeability
was calculated using the following formula: (BSA lower
chamber) × 100/(BSA upper chamber).
2.9. Statistical Analyses. All data were expressed as mean ±
SD. Statistical signiﬁcance for multiple comparisons was
determined using one-way ANOVAs and Tukey’s post hoc
tests with SPSS software (SPSS, Chicago, IL, USA). The
signiﬁcance threshold was set at P<0.05.
3. Results
3.1. Simvastatin Attenuates High Cholesterol Diet-Induced
Leakage of Evan’s Blue Dye In Vivo. BBB integrity was
assessed by Evans blue extravasation (Figure 1). Evans blue
is normally excluded from the brain parenchyma by the
BBB and is only detectable when the integrity of the BBB
is compromised. Increased BBB permeability was observed
in rabbits fed a high-cholesterol diet (supplemented with
2% cholesterol for 10 weeks), as evidenced by the increased
Evans blue content in their olfactory bulbs and hippocampi
when compared to those of rabbits fed a normal diet. Oral
administration of simvastatin at a dose of 5mg/kg/day for
4 weeks (weeks 7–10) attenuated the high cholesterol diet-
induced leakage of Evan’s blue dye in both the olfactory bulb
and the hippocampus.
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Figure 1: Simvastatin blocks high-cholesterol diet-induced leakage
of Evan’s blue dye. New Zealand White rabbits were fed a normal
diet (10 weeks) or a high-cholesterol diet (10 weeks) with or
without simvasatin (over the ﬁnal 4 weeks). After treatment, BBB
permeability was evaluated by measuring Evan’s blue dye leakage.
High-cholesterol diet signiﬁcantly increased the leakage of Evan’s
bluedyeintotheolfactorybulbsandhippocampus,andtheseeﬀects
were attenuated by treatment with simvastatin (5mg/kg/day during
weeks 7–10) (n = 8, ∗P<0.05; ∗∗P<0.01).
3.2. Simvastatin Had No Eﬀect on the High-Cholesterol Diet-
Induced Downregulation of Tight Junction Proteins In Vivo.
The tight junctions (TJs) between the endothelial cells
serve to restrict blood-borne substances from entering the
brain. ZO-1 and occluding were the major interendothelial
junctional proteins. Thus, to determine if the eﬀects of sim-
vastatin on BBB permeability resulted from alterations in the
major interendothelial junctional proteins, the expression
of ZO-1 and occludin was examined in rabbits fed a high-
cholesterol diet treated with simvastatin. The results revealed
decreased immunostaining for ZO-1 (Figures 2(a) and 3(a))
and occludin (Figures 2(b) and 3(b)) in the olfactory bulbs
and hippocampi of rabbits fed a high-cholesterol diet for 10
weeks when compared to rabbits fed a normal diet. However,
simvastatin (5mg/kg/day for 4 weeks) had no eﬀects on
either the expression of occludin or ZO-1.
3.3. Simvastatin Aﬀects Plasma Levels of Cholesterol but Not
Levels of Cholesterol in the Brain. Cholesterol seems to play
an important role in the development of AD. Therefore,
it is of interest to evaluate the eﬀects of high doses of
simvastatin on levels of cholesterol in serum and in brain.
As expected, rabbits fed a cholesterol-enriched diet for 10
weeks exhibited over a 20-fold increase in total serum
cholesterol concentration. Treatment of high-cholesterol-
diet-fed rabbits with simvastatin (5mg/kg/day for 4 weeks)
signiﬁcantly reduced plasma cholesterol levels. However,
cholesterol levels in the hippocampus and cortex were not
aﬀected by a cholesterol-enriched diet in the presence or
absence of simvastatin (Table 1).4 International Journal of Alzheimer’s Disease
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Figure 2: Simvastatin has no eﬀect on high-cholesterol diet-induced downregulation of tight junction proteins. Cryostat sections of the
olfactory bulbs and hippocampus were incubated with ﬂuorescently labeled antibodies against occludin and ZO-1, and representative
images for each treatment group are shown. (a) Decreased ZO-1 immunostaining was observed in the olfactory bulbs and hippocampus
of cholesterol-fed rabbits (supplemented with 2% cholesterol for 10 weeks). This eﬀect was not blocked by treatment with simvastatin
(5mg/kg/day for 4 weeks). (b) Decreased occludin immunostaining was observed both in the olfactory bulbs and hippocampus of
cholesterol-fed rabbits, and this eﬀect was not blocked by simvastatin (200×).
Table 1: Concentration of total cholesterol (TC) in the serum, cortex, and hippocampus of rabbits fed a control diet, high-cholesterol diet,
and high-cholesterol diet plus simvastatin.
Group Serum TC Cortex TC Hippocampus TC
Control diet 51.4 ± 9.96b 1.29 ±0.16 1.36 ±0.14
Cholesterol diet 1449.6 ±677.11 .25 ±0.13 1.31 ±0.23
Cholesterol diet + simvastatin 866.1 ± 147.46a 1.27 ±0.11 1.38 ±0.10
The concentration of total serum cholesterol is expressed as g/mL and the concentration of total cortex or hippocampus cholesterol is expressed as g/100g wet
weight of tissue. Data are expressed as means ± S.D. (n = 8; aP<0.05; bP<0.01; compared with Cholesterol diet).
3.4. Simvastatin Blocks the TEER Decline and Increased
Transendothelial Protein Permeability Induced by High Levels
of Cholesterol In Vitro. To further verify the observed eﬀects
of simvastatin, primary cultures of brain endothelial cells,
the most important component of the BBB, were examined.
Primary RBMECs were stimulated with cholesterol (10μM)
in the presence/absence of simvastatin (5μM) for 24h.
Potential changes in the integrity of the BBB were assessed
by measuring TEER and the permeability of an RBMEC
m o n o l a y e rt oF I T C - B S A .Figure 4(a) shows that cholesterol
markedly retarded the development of TEER of RBMEC
monolayersduring postconﬂuentgrowth.Asigniﬁcanteﬀect
of simvastatin (5μM) became visible after a 24h treatment
of RBMECs. Consistent with the results of TEER, cholesterol
was shown to induce increased permeability to the large
molecular weight tracer FITC-BSA, and this eﬀect was
signiﬁcantly blocked by simvastatin (Figure 4(b)).
4. Discussion
Our results showed that simvastatin signiﬁcantly reduces
leakage of Evan’s blue dye across the BBB but does notInternational Journal of Alzheimer’s Disease 5
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Figure 3: Simvastatin has no eﬀect on high-cholesterol diet-induced downregulation of tight junction proteins. Images from Figure 2 were
analyzed with Image J software. (a) Quantitative data from Figure 2(a) demonstrates that a high-cholesterol diet signiﬁcantly decreases
ZO-1 immunoreactivity in the olfactory bulbs and hippocampus, an eﬀect that was not blocked by simvastatin. (b) Quantitative data
from Figure 2(b) demonstrates that a high-cholesterol diet signiﬁcantly decreased occludin immunoreactivity in the olfactory bulbs and
hippocampus. However, this eﬀect was not blocked by simvastatin treatment (5mg/kg/day for 4 weeks) (n = 8, ∗P<0.05).
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Figure 4: Simvastatin blocks cholesterol-induced TEER decline and transendothelial permeability in vitro. Rat primary brain endothelial
c e l l sw e r es t i m u l a t e df o r2 4hw i t h1 0μM cholesterol in the presence or absence of simvastatin (5μM). TEER of conﬂuent RBMECs (a)
and permeability of FITC-BSA (b) were measured. Simvastatin signiﬁcantly blocks both the TEER decline and the increase in FITC-BSA
permeabilityinducedbyhighcholesterol(a,b).TEERwasexpressedinohmspersquarecentimeterforelectricalresistance(n = 8, ∗P<0.05;
∗∗P<0.01).
aﬀect the expressions of the tight junction proteins, occlud,
and ZO-1, in rabbits fed a cholesterol-rich diet. In addition,
our data indicate that simvastatin alters plasma levels of
cholesterol but does not aﬀect levels of cholesterol in the
brain. We also observed that cotreatment with simvastatin
blocked the cholesterol-induced increase in transendothelial
permeability and the cholesterol-induced decrease in TEER
observed in primary cultured RBMECs. The semipermeable
BBB restricts the diﬀusion of blood-borne substances into
the brain parenchyma. Disruptions in the BBB can cause
chemical imbalances in the neuronal “milieu,” ultimately
resulting in synaptic and neuronal dysfunction. Disruption
of the BBB is a hallmark of Alzheimer’s disease [10, 11].
Furthermore, elevated plasma cholesterol has been shown to
increaseBBBpermeabilityandisapossibleriskfactorforAD
[2, 23–26]. Consistent with the above ﬁndings, the present6 International Journal of Alzheimer’s Disease
study demonstrated that high levels of cholesterol can induce
leakageoftheBBBinvivoanddisrupttheintegrityofinvitro
models of the BBB.
AD, a type of dementia that aﬀects millions of elderly
individuals, is the fourth leading cause of death among
the elderly in developed countries [27]. Current therapeutic
interventions for AD are largely ineﬀective. Epidemiological
studies reveal a lower prevalence of AD in patients with
hypercholesterolemia who are taking statins, a frequently
prescribed class of lipid-lowering drugs [28, 29]. Several
experiments have shown that statins may be potentially
beneﬁcial in the treatment of AD via their direct eﬀects
on brain cholesterol metabolism [30, 31]. However, other
studies have failed to demonstrate a reduction in the
ratio between 24S-hydroxycholesterol and cholesterol, in
response to statin treatment [32]. At the same time, recent
retrospective epidemiological studies have reported that the
use of statins, but not nonstatin lipid-lowering agents, may
reduce the risk of developing AD [8, 12]. Consistent with
previous ﬁndings [33], our results also demonstrate that
short-term simvasatin treatment does not aﬀect brain total
cholesterol; however, it has an eﬀect on BBB integrity. This
result suggests that the mechanisms by which statins protect
against AD may extend beyond their lipid-lowering eﬀects.
Amyloid deposition is seen as the core pathological aspects
of AD. Cholesterol has been mainly considered for dementia
through promoting the generation of amyloid. However,
immunization trials targeting the removal of amyloid-β
plaques in Alzheimer’s disease have so far failed to stop the
progression of dementia. Recent data show that to reduce
oxidativestressandinﬂammation-relatedfactorsinthebrain
by interfering with the permeability of the BBB may enhance
the therapeutic eﬀect mentioned above [34]. Therefore,
to maintain the integrity of the BBB maybe more closely
associated with the action of simvastatin on preventing AD
instead of lipid-lowering eﬀects.
The current study provides the ﬁrst evidence for the
protective eﬀects of simvastatin against BBB disruptions
both in rabbits with hypercholesterolemia and in RBMECs
exposed to cholesterol-enriched media. In rabbits fed a high-
cholesterol diet, simvastatin reduced the leakage of Evan’s
blue dye into the olfactory bulb and hippocampus. To follow
up these ﬁndings, we subsequently carried out an in vitro
study using brain microvascular endothelial cells exposed to
10μM cholesterol as a model of BBB disruption. We found
that simvastatin blocks the TEER decline and increased
transendothelial permeability induced by high cholesterol, a
result that corresponded well with our observed results in
vivo. Because tight junctions between cerebral microvascular
endothelial cellsformthebasisoftheBBB[35],weexamined
the expression of two tight junction proteins, occludin and
ZO-1, after simvastatin treatment. However, we found that
simvasatin had no eﬀect on the expression of tight junction
proteins. These results suggest that simvastatin blocks BBB
leakage induced by elevated cholesterol, independent of
changes in the expression of the tight junction molecules,
occludinandzonulaoccluden-1.Thisﬁndingisinagreement
with at least one previous report in the literature [22], which
showed similar results in an in vitro model of multiple
sclerosis.
In the present study, we did not explore the detailed
molecular mechanisms whereby simvastatin protects against
BBB disruption. However, we did demonstrate that simvas-
tatin is eﬀective in ameliorating BBB disruption induced by
high-cholesterol diet in rabbits and in reducing cholesterol-
inducedendothelialpermeabilityinaninvitromodelofBBB
disruption.
5. Conclusion
To the best of our knowledge, the present study is the
ﬁrst to show that simvastatin improves BBB integrity both
in rabbits fed a high-cholesterol diet and in a cholesterol-
induced in vitro model of BBB disruption using primary
cultured RBMECs. Our data provide a new mechanism
underlying the neuroprotective activity of simvastatin and
suggest that simvastatin may be useful in the treatment of
BBB disruptions induced by hypercholesterolemia.
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